Literature DB >> 15121481

Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia.

Pavla Stopkova1, Takuya Saito, Demitri F Papolos, Jan Vevera, Ivo Paclt, Ilja Zukov, Yonina B Bersson, Benjamin A Margolis, Rael D Strous, Herbert M Lachman.   

Abstract

BACKGROUND: Genes involved in phosphoinositide (PI) lipid metabolism are excellent candidates to consider in the pathogenesis of bipolar disorder (BD) and schizophrenia (SZ). One is PIK3C3, a member of the phosphatidylinositide 3-kinase family that maps closely to markers on 18q linked to both BD and SZ in a few studies.
METHODS: The promoter region of PIK3C3 was analyzed for mutations by single-strand conformation polymorphism analysis and sequencing. A case-control association study was conducted to determine the distribution of variant alleles in unrelated patients from three cohorts. Electromobility gel shift assays (EMSA) were performed to assess the functional significance of variants.
RESULTS: Two polymorphisms in complete linked disequilibrium with each other were identified, -432C- > T and a "C" insert at position -86. The -432T allele occurs within an octamer containing an ATTT motif resembling members of the POU family of transcription factors. In each population analyzed, an increase in -432T was found in patients. EMSAs showed that a -432T containing oligonucleotide binds to brain proteins that do not recognize -432C.
CONCLUSIONS: A promoter mutation in a PI regulator affecting the binding of a POU-type transcription factor may be involved in BD and SZ in a subset of patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121481     DOI: 10.1016/j.biopsych.2004.01.014

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  33 in total

1.  Mutations in Vps15 perturb neuronal migration in mice and are associated with neurodevelopmental disease in humans.

Authors:  Thomas Gstrein; Andrew Edwards; Anna Přistoupilová; Ines Leca; Martin Breuss; Sandra Pilat-Carotta; Andi H Hansen; Ratna Tripathy; Anna K Traunbauer; Tobias Hochstoeger; Gavril Rosoklija; Marco Repic; Lukas Landler; Viktor Stránecký; Gerhard Dürnberger; Thomas M Keane; Johannes Zuber; David J Adams; Jonathan Flint; Tomas Honzik; Marta Gut; Sergi Beltran; Karl Mechtler; Elliott Sherr; Stanislav Kmoch; Ivo Gut; David A Keays
Journal:  Nat Neurosci       Date:  2018-01-08       Impact factor: 24.884

Review 2.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

3.  Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis.

Authors:  Wibke Bechtel; Martin Helmstädter; Jan Balica; Björn Hartleben; Betina Kiefer; Fatima Hrnjic; Christoph Schell; Oliver Kretz; Shuya Liu; Felix Geist; Dontscho Kerjaschki; Gerd Walz; Tobias B Huber
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

4.  No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.

Authors:  Jie Li; Xue Li; Emily Liu; Paul Copeland; Oliver Freudenreich; Donald C Goff; David C Henderson; Xueqin Song; Xiaoduo Fan
Journal:  Schizophr Res       Date:  2013-02-21       Impact factor: 4.939

Review 5.  Cellular and molecular interactions of phosphoinositides and peripheral proteins.

Authors:  Robert V Stahelin; Jordan L Scott; Cary T Frick
Journal:  Chem Phys Lipids       Date:  2014-02-17       Impact factor: 3.329

Review 6.  Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia.

Authors:  Bernard Crespi; Philip Stead; Michael Elliot
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-01       Impact factor: 11.205

7.  No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.

Authors:  Xiaoduo Fan; Emily Liu; Oliver Freudenreich; Paul Copeland; Douglas Hayden; Musie Ghebremichael; Bruce Cohen; Dost Ongur; Donald C Goff; David C Henderson
Journal:  J Clin Psychopharmacol       Date:  2013-04       Impact factor: 3.153

8.  Endosomal Phosphatidylinositol 3-Phosphate Promotes Gephyrin Clustering and GABAergic Neurotransmission at Inhibitory Postsynapses.

Authors:  Theofilos Papadopoulos; Hong Jun Rhee; Devaraj Subramanian; Foteini Paraskevopoulou; Rainer Mueller; Carsten Schultz; Nils Brose; Jeong-Seop Rhee; Heinrich Betz
Journal:  J Biol Chem       Date:  2016-12-09       Impact factor: 5.157

9.  Novel association strategy with copy number variation for identifying new risk Loci of human diseases.

Authors:  Xianfeng Chen; Xinlei Li; Ping Wang; Yang Liu; Zhenguo Zhang; Guoping Zhao; Haiming Xu; Jun Zhu; Xueying Qin; Suchao Chen; Landian Hu; Xiangyin Kong
Journal:  PLoS One       Date:  2010-08-20       Impact factor: 3.240

10.  Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.

Authors:  Silvia N Kariuki; Beverly S Franek; Rachel A Mikolaitis; Tammy O Utset; Meenakshi Jolly; Andrew D Skol; Timothy B Niewold
Journal:  J Biomed Biotechnol       Date:  2010-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.